RPO LLC’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

RPO LLC’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-19,012	Closed	-$191K	–	210
2022 Q3	$191K	Buy	+19,012	New	+$189K	0.05%	155

Other funds holding EUCR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

RPO LLC's EUCR Position: Q4 2022 in Review

RPO LLC sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 19,012 shares — an estimated $191K sold.

RPO LLC first reported a position in EUCR in Q3 2022 and held it in 1 quarter. The position peaked at $191K in Q3 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

RPO LLC reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
RPO LLC sold 19,012 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $191K.
RPO LLC first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q3 2022 and held it in 1 quarter.
RPO LLC's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $191K in Q3 2022.
5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on RPO LLC's 13F filing for Q4 2022, filed 10 Feb 2023.